Stock Track | Hims & Hers Health Soars 5.34% in Pre-Market on Strong Q4 Results, Weight-Loss Sales

Stock Track

Feb 26, 2025

Hims & Hers Health Inc. (HIMS) stock surged 5.34% in Wednesday's pre-market session, rebounding after last week's selloff. The telehealth company's shares are rallying following its robust fourth-quarter earnings report and upbeat outlook, driven by strong demand for its weight-loss offerings.

The company reported a massive 95% year-over-year revenue jump to $481.1 million in Q4, fueled by robust sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue skyrocketed 69% to $1.48 billion. Looking ahead, the company forecasted Q1 2025 revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.

However, investors had previously sent the stock tumbling 22% last week after the FDA announced that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting demand for Hims & Hers' offerings. Nonetheless, the company's strong performance and optimistic guidance seem to have revived investor confidence, driving the pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1164721066"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164721066\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164721066?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164721066","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.34% in Pre-Market on Strong Q4 Results, Weight-Loss Sales","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) stock surged 5.34% in Wednesday's pre-market session, rebounding after last week's selloff. The telehealth company's shares are rallying following its robust fourth-quarter earnings report and upbeat outlook, driven by strong demand for its weight-loss offerings.</p>\n\n<p>The company reported a massive 95% year-over-year revenue jump to $481.1 million in Q4, fueled by robust sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue skyrocketed 69% to $1.48 billion. Looking ahead, the company forecasted Q1 2025 revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.</p>\n\n<p>However, investors had previously sent the stock tumbling 22% last week after the FDA announced that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting demand for Hims & Hers' offerings. Nonetheless, the company's strong performance and optimistic guidance seem to have revived investor confidence, driving the pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.34% in Pre-Market on Strong Q4 Results, Weight-Loss Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.34% in Pre-Market on Strong Q4 Results, Weight-Loss Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) stock surged 5.34% in Wednesday's pre-market session, rebounding after last week's selloff. The telehealth company's shares are rallying following its robust fourth-quarter earnings report and upbeat outlook, driven by strong demand for its weight-loss offerings.</p>\n\n<p>The company reported a massive 95% year-over-year revenue jump to $481.1 million in Q4, fueled by robust sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue skyrocketed 69% to $1.48 billion. Looking ahead, the company forecasted Q1 2025 revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.</p>\n\n<p>However, investors had previously sent the stock tumbling 22% last week after the FDA announced that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting demand for Hims & Hers' offerings. Nonetheless, the company's strong performance and optimistic guidance seem to have revived investor confidence, driving the pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1164721066","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164721066","pubTimestamp":1740581222,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  stock surged 5.34% in Wednesday's pre-market session, rebounding after last week's selloff. The telehealth company's shares are rallying following its robust fourth-quarter earnings report and upbeat outlook, driven by strong demand for its weight-loss offerings.The company reported a massive 95% year-over-year revenue jump to $481.1 million in Q4, fueled by robust sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue skyrocketed 69% to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪Hims&Hers Health因强劲的第四季度业绩和减肥销售而盘前飙升5.34%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) stock surged 5.34% in Wednesday's pre-market session, rebounding after last week's selloff. The telehealth company's shares are rallying following its robust fourth-quarter earnings report and upbeat outlook, driven by strong demand for its weight-loss offerings.\nThe company reported a massive 95% year-over-year revenue jump to $481.1 million in Q4, fueled by robust sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue skyrocketed 69% to $1.48 billion. Looking ahead, the company forecasted Q1 2025 revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.\nHowever, investors had previously sent the stock tumbling 22% last week after the FDA announced that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting demand for Hims & Hers' offerings. Nonetheless, the company's strong performance and optimistic guidance seem to have revived investor confidence, driving the pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}